Camrelizumab plus chemotherapy or apatinib in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma: A double-cohort phase II study.

Authors: Guoxin Ren, Houyu Ju, Rong-hui Xia, Jingzhou Hu, Yunteng Wu, Chenping Zhang, Xu Ding, Heming Wu, Shizhou Zhang, Yue He

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e18005

Source: Full article

---

Abstract

e18005